Welcome to our dedicated page for Immunitybio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on Immunitybio stock.
ImmunityBio, Inc. reports developments as a commercial-stage biotechnology company focused on immunotherapies designed to activate innate and adaptive immune responses for cancer and infectious disease. Its news centers on ANKTIVA® (nogapendekin alfa inbakicept-pmln), an IL-15 superagonist used with BCG for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors.
Recurring updates cover ANKTIVA product revenue and unit demand, global regulatory authorizations and commercial availability, distribution partnerships, and scientific presentations involving bladder cancer, lung cancer, and broader IL-15 oncology programs. Company announcements also address BCG-naïve NMIBC clinical development, FDA promotional-compliance correspondence, and financing arrangements tied to revenue interests and convertible debt.
ImmunityBio (NASDAQ: IBRX) has commenced trading as a large-cap company with approximately 398 million fully diluted shares following its merger with NantKwest. The combined entity is now listed on the Global Select Market of Nasdaq. ImmunityBio specializes in late-stage immunotherapy, focusing on innovative therapies for cancer and infectious diseases, backed by a pipeline of over 40 clinical trials in development across 19 indications. Its lead product, Anktiva™, has received favorable FDA designations for certain bladder cancer treatments.